title: Pharmacological characterization of the late phase reduction in lung functions and correlations with microvascular leakage and lung edema in allergen-challenged Brown Norway rats.
abstract: Late phase airflow obstruction and reduction in forced vital capacity are characteristic features of human asthma. Airway microvascular leakage and lung edema are also present in the inflammatory phase of asthma, but the impact of this vascular response on lung functions has not been precisely defined. This study was designed to evaluate the role of increased lung microvascular leakage and edema on the late phase changes in forced vital capacity (FVC) and peak expiratory flow (PEF) in allergen-challenged Brown Norway rats using pharmacological inhibitors of the allergic inflammatory response. Rats were sensitized and challenged with ovalbumin aerosol and forced expiratory lung functions (FVC, PEF) and wet and dry lung weights were measured 48 h after antigen challenge. Ovalbumin challenge reduced FVC (63% reduction) and PEF (33% reduction) and increased wet (65% increase) and dry (51% increase) lung weights. The antigen-induced reduction in FVC and PEF was completely inhibited by oral treatment with betamethasone and partially attenuated by inhibitors of arachidonic acid metabolism including indomethacin (cyclooxygenase inhibitor), 7-TM and MK-7246 (CRTH2 antagonists) and montelukast (CysLT1 receptor antagonist). Antagonists of histamine H1 receptors (mepyramine) and 5-HT receptors (methysergide) had no significant effects indicating that these pre-formed mast cell mediators were not involved. There was a highly significant (P < 0.005) correlation for the inhibition of FVC reduction and increase in wet and dry lung weights by these pharmacological agents. These results strongly support the hypothesis that lung microvascular leakage and the associated lung edema contribute to the reduction in forced expiratory lung functions in antigen-challenged Brown Norway rats and identify an important role for the cyclooxygenase and lipoxygenase products of arachidonic acid metabolism in these responses.
authors.affiliation: Merck Research Laboratories, 2015, Galloping Hill Road, Kenilworth, NJ 07033-0539, USA. Electronic address: peter.mauser2@merck.com.
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Mauser
authors.forename: Aileen
authors.initials: A
authors.lastname: House
authors.forename: Howard
authors.initials: H
authors.lastname: Jones
authors.forename: Craig
authors.initials: C
authors.lastname: Correll
authors.forename: Christopher
authors.initials: C
authors.lastname: Boyce
authors.forename: Richard W
authors.initials: RW
authors.lastname: Chapman
mesh_terms: D000485:Allergens / Q000276:immunology; D000818:Animals; D016718:Arachidonic Acid / Q000378:metabolism*; D001249:Asthma / Q000503:physiopathology; D001623:Betamethasone / Q000494:pharmacology; D002199:Capillary Permeability / Q000187:drug effects / Q000502:physiology; D004195:Disease Models, Animal; D007249:Inflammation / Q000276:immunology / Q000503:physiopathology*; D008084:Lipoxygenase / Q000378:metabolism; D008297:Male; D055806:Microvessels / Q000276:immunology / Q000473:pathology*; D010047:Ovalbumin / Q000276:immunology; D010366:Peak Expiratory Flow Rate; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism; D011654:Pulmonary Edema / Q000276:immunology / Q000503:physiopathology*; D051381:Rats; D011914:Rats, Inbred BN; D014797:Vital Capacity
chemical_list: D000485:Allergens; D016718:Arachidonic Acid; D010047:Ovalbumin; D001623:Betamethasone; D008084:Lipoxygenase; D011451:Prostaglandin-Endoperoxide Synthases
keywords: Brown Norway rats; Forced expiratory maneuvers; Inflammation; Mediators of inflammation; Pulmonary edema